AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Anixa Biosciences Receives Additional US Patent for CAR-T Technology, Extending Protection to 2045
ByAinvest
Tuesday, Aug 12, 2025 2:17 pm ET1min read
Anixa Biosciences has received a US patent for its CAR-T technology from the US Patent and Trademark Office, extending protection to 2045. This technology is used in cancer immunotherapy, which involves using genetically modified T cells to target and destroy cancer cells. The patent covers Anixa's CAR-T technology, which is a significant development for the company.
Anixa Biosciences (NASDAQ: ANIX) has received a significant boost as the United States Patent and Trademark Office (USPTO) has issued a U.S. patent covering its chimeric antigen receptor-T cell (CAR-T) technology. This patent, which extends protection to 2045, encompasses core methods and compositions fundamental to Anixa's CAR-T approach. The patent was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences.The CAR-T technology, currently in clinical trials at Moffitt Cancer Center for the treatment of recurrent ovarian cancer, represents a significant advancement in cancer immunotherapy. This approach involves using genetically modified T cells to target and destroy cancer cells, offering a promising avenue for personalized cancer treatment.
The patent issuance comes at a crucial time for Anixa Biosciences, which is already seeing positive market reception. The company's shares were up more than 3% in premarket trading following the announcement, reflecting investor confidence in the company's technological advancements and clinical progress.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) also recently made headlines with the FDA approval of the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). This approval marks a significant milestone in the development of breakthrough immunomodulation therapies for an unmet medical need.
These developments underscore the ongoing innovation and progress in the biotechnology sector, particularly in the areas of cancer immunotherapy and neuroinflammation treatment.
References:
[1] https://seekingalpha.com/news/4483856-anixa-biosciences-announces-issuance-of-additional-us-patent-for-car-t-technology
[2] https://www.biospace.com/press-releases/fda-approves-tiziana-life-sciences-phase-2-ind-for-multiple-system-atrophy
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet